Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2012 Financial Results
Date:11/13/2012

Urinary Conduit died due to afflictions unrelated to the product candidate or the surgical procedure. The fourth patient enrolled in the trial died of metastatic bladder cancer and the sixth patient passed away from a cardiopulmonary arrest following a myocardial infarction. Until their deaths, both patients' Neo-Urinary Conduits functioned well and they maintained normal renal function.

Following a positive meeting with the Data Safety Monitoring Board (DSMB) and the U.S. Food and Drug Administration (FDA), the Company is proceeding with concurrent enrollment of the remaining four patients in the Phase 1 clinical trial. Tengion is actively recruiting and remains focused on enrolling the remaining four patients in the trial by the end of 2012, however the timing of enrolling the seventh patient may result in completing enrollment of this trial in the first quarter of 2013.

There are four clinical trial sites actively recruiting patients for this clinical trial. These include the two original centers, the University of Chicago Medical Center and The Johns Hopkins Hospital in Baltimore, MD, as well as Baylor College of Medicine in Houston, TX and University of Michigan Comprehensive Cancer Center in Ann Arbor, MI. An additional two clinical trial sites are open for enrollment but are not yet actively recruiting patients.

Neo-Kidney Augment Preclinical Program UpdateTengion's lead preclinical program, the Neo-Kidney Augment, is intended to prevent or delay the need for dialysis or kidney transplant by catalyzing the regeneration of functional kidney tissue in patients with advanced chronic kidney disease (CKD).

Tengion is currently conducting the good laboratory practice (GLP) animal study program required by the FDA to support an Investigational New Drug (IND) filing and initiation of a Phase 1 clinical trial in CKD patients. These GLP studies are consistent with the preclinical animal models already conducted by Tengion, which yielded po
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
2. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
3. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. New Resource Provides Herb Industry With Sources of Quality Specifications
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
8. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
9. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
10. Insmed Incorporated Provides Corporate Update
11. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Spirax Sarco, the leader ... their newly designed, state-of-the-art website in the first ... effectively promotes the Spirax Sarco brand, company capabilities, ... that a site visitor might be looking for ... industries serviced, the latest company news, careers, and ...
(Date:4/16/2015)... CA (PRWEB) April 16, 2015 Cytokinetics, ... to report first quarter results on Thursday, April 30, ... Cytokinetics’ senior management will host a conference call at ... results and the company’s outlook for the future. , ... be accessed from the homepage and in the Investor ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, Inc., ... has signed a long-term lease on Laboratory Drive in ... Carolina . The location will house review board ... provide high quality reviews and customer service to clients. ... represented Schulman in the deal, while Capital Associates ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
Breaking Biology Technology:Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company ... today reported its highlights and financial results for the third ... Quarter Highlights , In the third quarter of ... pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the ...
... Nov. 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP Therapeutic(TM) ... at 2:20 pm ET on Tuesday, November 10, 2009 at ... be held in New York City. , The presentation will ...
... WILMINGTON, Delaware, November 3 The ... Technologies Market, (2009 - 2014),published by MarketsandMarkets ( ... stem cell market. It identifies and analyzes,the main ... services, technologies, and applications submarkets in different,geographic regions. ...
Cached Biology Technology:VIVUS Reports Third Quarter 2009 Highlights and Financial Results 2VIVUS Reports Third Quarter 2009 Highlights and Financial Results 3VIVUS Reports Third Quarter 2009 Highlights and Financial Results 4VIVUS Reports Third Quarter 2009 Highlights and Financial Results 5VIVUS Reports Third Quarter 2009 Highlights and Financial Results 6VIVUS Reports Third Quarter 2009 Highlights and Financial Results 7VIVUS Reports Third Quarter 2009 Highlights and Financial Results 8Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the dead bone of a transplanted skeletal graft into living ... gene therapy to stimulate the body into treating the foreign ... thousands of cancer and trauma patients each year who suffer ... online Feb. 13 and will appear in the March 1 ...
... Malignancies Program at the H. Lee Moffitt Cancer Center ... of the experimental drug Revlimid showing promise as an ... a form of pre-leukemia. Given in pill form, Revlimid ... nourish tumors (anti-angiogenesis) and stimulates the immune system to ...
... many years, DNA and proteins have been,viewed as ... with RNA seen,as little more than a messenger ... Whitehead Institute for Biomedical Research,and Massachusetts Institute of ... regulate thousands of human genes--more,than one third of ...
Cached Biology News:Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4Leukemia Drug Breakthrough Study In New England Journal Of Medicine 2NYU researchers simulate molecular biological clock 2
... 1-D PAGE Cleavable ICAT ... Targeted Protein ID and ... Gel Electrophoresis (PAGE), isotope-coded ... cleavable-linker technology to facilitate ...
Supplemental reagent for annexin V assay....
Antibody Purification Specificity: Antibody Purification ...
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: